ArticleBiochemia medica2023
Definition of icteric interference index for six biochemical analytes.
Article in Biochemia medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and Evaluation of Artificial Intelligence-Based Two-Step Model for Automated Serum Quality Assessment in Clinical Laboratories.Annals of laboratory medicine · 2026Article
- Optimization of icterus interference thresholds for 45 parameters on the Atellica analyzers CH930 and IM1300.Biochemia medica · 2026Article
- Utility of the I-index as a pre-screening tool for total bilirubin testing: a retrospective study in a regional hospital.Advances in laboratory medicine · 2026Article
- Preanalytical Errors in Clinical Laboratory Testing at a Glance: Source and Control Measures.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Icterus, if not detected, can affect the validity of results delivered by clinical laboratories, leading to erroneous results. This study aims to define bilirubin interference for some biochemical analytes and compare it with the manufacturer's data. Material and methods: Serum pools prepared with outpatients' samples were spiked with increasing bilirubin concentration (Merck, reference14370, Darmstadt, Germany) up to 513 µmol/L in order to evaluate the bias for the following biochemical analytes: creatinine (CREA), creatine kinase (CK), cholesterol (CHOL), gamma-glutamyltransferase (GGT), high-density lipoprotein cholesterol (HDL), and total protein (TP). For each analyte, six pools of different concentrations were prepared. Measurements were made employing Cobas 8000 analyser c702-502, Roche Diagnostics (Mannheim, Germany). This study employed a study procedure defined by the Spanish Society of Laboratory Medicine. Results: Obtained bilirubin concentrations producing a negative interference were 103 µmol/L for CHOL, 205 µmol/L for TP and 410 µmol/L for CK, but only for CK values less than 100 U/L. Bilirubin concentrations lower than 513 µmol/L do not produce interference for HDL and GGT. Finally, for the studied bilirubin concentrations, there is no interference for CREA higher than 80 µmol/L. Conclusion: Icterus interferences have been defined for each analyte, observing differences compared to data provided by the manufacturer. The evidence indicates that each laboratory should evaluate icteric interferences to ensure the high quality of the delivered results, thus benefiting patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.